Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03352427|
Recruitment Status : Terminated (Low accrual)
First Posted : November 24, 2017
Results First Posted : October 5, 2022
Last Update Posted : October 5, 2022
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Glioma High Grade Glioma Pontine Tumors||Drug: Dasatinib Drug: Everolimus||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||3 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 2 Study of Dasatinib in Combination With Everolimus for Children With Gliomas Harboring PDGFR Alterations|
|Actual Study Start Date :||December 6, 2017|
|Actual Primary Completion Date :||April 17, 2019|
|Actual Study Completion Date :||May 15, 2019|
Dasatinib = 60 mg/m2 orally twice daily
Everolimus = starting dose of 3.0 mg/m2, with titration of dosing after first cycle to keep everolimus trough level of 5-15 ug/ml
Both agents will be taken daily for 28 day cycles. Cycles will be repeated every 28 days and patients may receive up to 24 cycles.
60 mg/m2 orally twice daily
3.0 mg/m2, with titration of dosing after first cycle to keep trough level of 5-15 ug/ml
- Progression-free Survival in Participants With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) [ Time Frame: 8 months ]Percentage of participants without progression, defined as 25% increase in the size of the tumor or appearance of new lesions.
- Progression-free Survival in Participants With Newly Diagnosed High-grade Glioma (HGG) [ Time Frame: 12 months ]Percentage of participants without progression, defined as 25% increase in the size of the tumor or appearance of new lesions.
- Overall Response Rate (OR) (Partial Response or Better) in Participants With Refractory or Recurrent Glioma [ Time Frame: 56 Days ]The overall response assessment will take into account response in both target and non-target lesions, as well as the appearance of new lesions. Partial Response (PR) will be defined as ≥50% decrease in size of tumor in comparison to baseline measurements. Complete Response (CR) will be defined as the disappearance of all abnormal signal. This includes return to normal size of the brain stem for brain stem lesions. Reported as percentage of participants with partial or better response at 56 days.
- Overall Survival [ Time Frame: 1 year ]Percentage of patients alive at one year.
- Overall Survival [ Time Frame: up to 17 months ]Percentage of participants alive at 2 years.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||1 Year to 50 Years (Child, Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Histological confirmation of a newly diagnosed high-grade glioma or diffuse intrinsic pontine glioma (DIPG) (Stratum A)
- Histological confirmation (at diagnosis or relapse) of a recurrent or progressive grade II-IV glioma (including DIPG) (Stratum B)
- Participants must have a genomic (DNA and/or RNA) alteration (mutation, fusion, and/or amplification) involving PDGF-A, PDGF-B, PDGFR-A or PDGFR-B, as identified by tumor sequencing.
- Age at enrollment: Greater than 1 year and less than 50 years
- BSA (body surface area): BSA greater than 0.3 m2
- Karnofsky (Measure of performance for cancer patients where 100% represents perfect health) > 50% for patients > 16 years of age and Lansky (Measure of performance for pediatric cancer patients where 100% represents perfect health) > 50% for patients < 16 years of age. Neurologic deficits in patients with CNS tumors must have been relatively stable for a minimum of 7 days. Patients who are unable to walk because of paralysis, but who are able to sit in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
- Adequate bone marrow function per protocol
- Adequate liver function per protocol
- Adequate renal and metabolic function per protocol
- Patients with known seizure disorder must have seizures adequately controlled with non- enzyme inducing antiepileptic medications
- No increase in steroid dose within the past 7 days
- Primary brain or spine tumor are eligible, including tumors with metastases, multiple lesions.
- Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy.
- Myelosuppressive chemotherapy: Must not have received within 3 weeks.
- Hematopoietic growth factors: At least 7 days since the completion of therapy with a growth factor, 14 days for long- acting.
- Biologic (anti-neoplastic agent): At least 7 days or 3 half-lives (whichever is longer) since the completion of therapy.
- Stratum A: ≥ 2 weeks and </= to 12 weeks must have elapsed from radiation.
- Stratum B: ≥ 2 weeks must have elapsed from focal radiation.
- > 3 weeks from major surgery. If recent craniotomy, adequate wound healing must be determined by neurosurgical team.
- Autologous Stem Cell Transplant or Rescue: No evidence of active graft vs. host disease and ≥ 4 weeks must have elapsed.
- All patients and/or a legal guardian must sign institutionally approved written informed consent and assent documents.
- Patients who are breastfeeding, pregnant or refuse to use an effective form of birth control are excluded.
- Patients with uncontrolled infection are excluded.
- Patients receiving other anti-neoplastic agents are excluded.
- Patients requiring strong CYP3A4 or PGP inhibitors are excluded (per protocol)
- Patients requiring anticoagulation or with uncontrolled bleeding are excluded.
- Patients on steroids for symptom management must be on a stable dose for 7 days prior to start of treatment.
- Patients within 1 year of allogeneic stem cell transplant, patients with active GVHD or requiring immunosuppression are excluded.
- Previous hypersensitivity to rapamycin or rapamycin derivatives
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03352427
|United States, Michigan|
|University of Michigan Cancer Center|
|Ann Arbor, Michigan, United States, 48109|
|Principal Investigator:||Carl Koschmann, M.D.||University of Michigan Rogel Cancer Center|
Documents provided by University of Michigan Rogel Cancer Center:
|Responsible Party:||University of Michigan Rogel Cancer Center|
|Other Study ID Numbers:||
HUM00123094 ( Other Identifier: University of Michigan )
|First Posted:||November 24, 2017 Key Record Dates|
|Results First Posted:||October 5, 2022|
|Last Update Posted:||October 5, 2022|
|Last Verified:||September 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Brain Stem Neoplasms
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Central Nervous System Diseases
Nervous System Diseases
Protein Kinase Inhibitors
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs